Adaptive Radiation for Abdominopelvic Metastases

ClinicalTrials.gov ID: NCT05880667

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05880667. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Adaptive Radiation for Abdominopelvic Metastases (ARAM)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Single arm Phase I trial of adaptive stereotactic body radiation (SBRT) for abdominopelvic metastases. Adaptive SBRT will allow for escalation of the prescription dose and target coverage while maintaining grade 3+ toxicity no greater than 10%. Subjects with metastatic cancer to the abdomen or pelvis requiring local control or palliation will be enrolled.

Study identification

NCT ID: NCT05880667
Recruitment status: Suspended
Study type: Interventional
Phase: Phase 1
Lead sponsor: Fox Chase Cancer Center; Other
Enrollment: 30 participants

Conditions and interventions

Conditions

Interventions

Adaptive Stereotactic Body Radiation Radiation

Radiation

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 1, 2023 (Actual)
Primary completion: Jun 1, 2028 (Estimated)
Completion: Jun 1, 2029 (Estimated)
Last update posted: Nov 2, 2026

2023 – 2029

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05880667, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 2, 2026 · Synced Nov 15, 2026